Skip to main content

Strategic Directions

Help NIA map out our strategic direction

As you know, NIA’s Strategic Directions document serves several purposes. It acts as a point of reference for setting scientific priorities; a framework for systematic analysis of the NIA’s research portfolio; and a benchmark against which we can assess progress. Perhaps most importantly, the Strategic Directions are a definitive statement of the NIA’s scientific priority areas within the rapidly evolving field of aging research.

NIH's priorities in Alzheimer's disease and related dementias: Let your voice be heard!

Research on Alzheimer’s disease and related dementias (AD/ADRD) is an important component of the NIA’s mission. In recent years, Congress has provided a significant amount of additional funding beyond our typical appropriation for us to accelerate research on the basic biology, prevention, diagnosis, treatment, and care related to this devastating group of diseases. With this additional funding comes the responsibility to plan and set priorities for the funds’ use.

NIA's updated strategic directions: A roadmap for progress

At the National Institute on Aging, our shared vision is one in which all Americans enjoy robust health and independence with advancing age. Although we have come far in 40 years of supporting and  conducting research, we in the scientific community will need to think broadly, creatively, intelligently—and strategically—to pursue this goal most effectively. I am proud to let you know that an updated version of NIA’s Strategic Directions, Aging Well in the 21st Century, is now available.

AGS 2021: Connect with cutting-edge research, care strategies, and colleagues!

Join us online for the 2021 American Geriatrics Society scientific meeting, featuring key sessions for early-career and established researchers!

Advancing Alzheimer’s and related dementias research: FY 2022 NIH bypass budget and progress report

The annual NIH Professional Judgment Budget for Alzheimer’s Disease and Related Dementias is out! Read it to learn more about how NIH investments have led to new science advances, then apply for funding opportunities to help us meet our goals for future research progress.

NIA’s Strategic Directions: Priorities for continued progress

NIA’s Strategic Directions document for 2020-2025 is now available. It provides a point of reference for setting future priorities and a framework for systematically analyzing the institute’s scientific portfolio and assessing progress. For researchers, it clearly signals NIA’s scientific priority areas within the rapidly evolving field of aging research.

NIA's 2020 vision: Continued advancements in aging research!

Ready for a new year of tackling the many opportunities and challenges in research on aging related biology, diseases and wellness? NIA is off to another monumental start: Our FY2020 budget indicates continued congressional support for our work that is enabling unprecedented advances, including efforts to combat Alzheimer’s disease and...

Austin City Limits: Join NIA at GSA!

Austin, TX, is the scene for the 2019 annual meeting of the Gerontological Society of America on November 13–17. This year’s theme is “Strength in Age: Harnessing the Power of Networks,” and it’s an excellent opportunity to strengthen your network by talking with NIA staff to learn about funding opportunities...

Cognitive reserve research reaches for the STARRRS

How do some older adults retain relatively normal or youthful thinking and memory abilities despite the presence of neurodegeneration or Alzheimer’s-related pathology in the brain? This phenomenon, known as cognitive reserve, is the subject of not only an upcoming new data and biomedical sample resource, but also a related request...

Seeking alternative animal models for Alzheimer's disease

Although knowledge of Alzheimer’s biology has advanced tremendously during the past three decades, many efforts to develop effective drugs or treatments have been unsuccessful. So, while we have been able to cure the disease in mouse models of the disease, we have not been able to translate these advances to...